Dimensional Fund Advisors LP Has $15.91 Million Holdings in CareDx, Inc (NASDAQ:CDNA)

Dimensional Fund Advisors LP trimmed its stake in CareDx, Inc (NASDAQ:CDNA) by 1.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 743,004 shares of the company’s stock after selling 7,853 shares during the period. Dimensional Fund Advisors LP’s holdings in CareDx were worth $15,907,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Thompson Davis & CO. Inc. lifted its stake in shares of CareDx by 6.3% in the fourth quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company’s stock worth $344,000 after acquiring an additional 950 shares during the period. Legal & General Group Plc lifted its position in shares of CareDx by 1.3% in the 4th quarter. Legal & General Group Plc now owns 89,751 shares of the company’s stock worth $1,922,000 after purchasing an additional 1,118 shares during the period. Sterling Capital Management LLC boosted its stake in shares of CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock valued at $27,000 after purchasing an additional 1,126 shares during the last quarter. Principal Financial Group Inc. raised its stake in CareDx by 6.5% during the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company’s stock worth $406,000 after buying an additional 1,151 shares during the last quarter. Finally, Plato Investment Management Ltd lifted its holdings in CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after buying an additional 1,370 shares during the period.

Insider Transactions at CareDx

In other CareDx news, Director Christine Cournoyer sold 16,700 shares of the business’s stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total value of $235,971.00. Following the transaction, the director now owns 37,045 shares of the company’s stock, valued at approximately $523,445.85. The trade was a 31.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Peter Maag sold 13,281 shares of the firm’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the sale, the director now directly owns 316,743 shares of the company’s stock, valued at approximately $5,457,481.89. This represents a 4.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,246 shares of company stock worth $469,498 in the last 90 days. Insiders own 4.90% of the company’s stock.

CareDx Stock Up 4.4 %

CDNA stock opened at $15.42 on Friday. The firm has a market capitalization of $858.49 million, a PE ratio of -5.71 and a beta of 2.27. CareDx, Inc has a twelve month low of $9.99 and a twelve month high of $34.84. The stock’s 50 day moving average is $17.97 and its 200-day moving average is $21.21.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.03. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $84.69 million for the quarter, compared to analysts’ expectations of $84.56 million. During the same period last year, the business earned ($0.03) EPS. The business’s revenue was up 17.6% on a year-over-year basis. On average, equities research analysts anticipate that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CDNA shares. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and lowered their price objective for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. HC Wainwright restated a “neutral” rating and issued a $25.00 price target on shares of CareDx in a report on Monday. Stephens reiterated an “overweight” rating and set a $40.00 price objective on shares of CareDx in a report on Monday. StockNews.com downgraded CareDx from a “buy” rating to a “hold” rating in a research note on Monday. Finally, The Goldman Sachs Group dropped their price target on CareDx from $34.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.